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Ledderhose disease (LD) is a benign and rare fibro-matosis of the foot, involving the plantar aponeuro-sis. LD has been described as similar to Dupuytren 
disease (DD).1
It can occur more commonly in males, at all ages, espe-
cially between third and fifth decades, often with bilateral 
involvement.1
Unlike DD, LD is often symptomatic, with frequent 
pain episodes, plantar swelling, and in advanced cases, 
retractions and fascial contractures.1–3
Surgical treatment is sometimes burdened with wound 
dehiscence, pathologic and painful scars, and possible 
recurrence.2 Furthermore, patients are forbidden to walk 
until the wounds are closed.
Several nonsurgical treatments have been proposed to 
avoid complications from surgical operation, with some 
convincing results.1–4
We report a case of bilateral symptomatic LD success-
fully treated with intranodular injection of collagenase of 
Clostridium hystoliticum (CCH). The patient was permitted 
to walk immediately after the injection. No significant side 
effects were observed.
CASE REPORT
A 59-year-old male patient, affected by recurrent bilat-
eral DD, reported smoking, diabetes, and systemic arte-
rial hypertension. The patient reported a 5-year onset LD 
of the right foot and 3-year onset of the left foot. Both 
sides presented with a nodule of the first ray, just proxi-
mally to metatarsophalangeal joint. Until surgical treat-
ment both feet were symptomatic. Pain limited walking 
and even worse running (Visual Analogue Scale right: 6.2; 
Visual Analogue Scale left: 5.1). He tried orthotics for 1 
year without benefits. No more treatments were previously 
performed.
In our institution, we are experienced in surgical 
treatment of LD. However, for a short time now, we have 
been using CCH to treat DD with very promising results. 
Hence CCH has become the first choice for treatment of 
DD in our institution. CCH was proposed to our patient 
suffering from LD as an alternative to traditional surgical 
therapy. The patient was completely informed about the 
unusual application of the drug. He refused surgery, con-
sidering postoperative walking limitation unacceptable, 
and approved the CCH injection.
The right side, which was the most painful one, was 
injected first. The injection was performed according to 
traditional technique.4 The procedure was performed in 
the operating room. The patient remained awake with 
anesthesiologic assistance. We injected 0.58 mg of reconsti-
tuted drug in a volume of 0.25 mL into the palpable nod-
ule (intranodular injection) (Fig. 1). No passive extension 
was provided after injection, unlike DD treatment. After 
the procedure, a soft dressing was applied. The patient 
was allowed to load the lower limb until tolerance level. 
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Summary: Ledderhose disease (LD) is a rare plantar fibromatosis of the foot, fre-
quently associated with Dupuytren disease. Collagenase of Clostridium hystoliticum 
has recently revolutionized the way to treat Dupuytren disease. Nevertheless, the 
literature is still critically lacking about the use of collagenase injection in LD. 
We report a case of a man with bilateral symptomatic LD treated with collage-
nase. Injections (0.58 mg of collagenase of C. hystoliticum) were performed into 
nodules. Forced extension after injection was not performed. The patient could 
walk normally immediately after procedure. The procedure was a complete suc-
cess without side effects or complications on either foot. Currently, at 14 months 
after treatment of the right foot and 12 months after treatment of the left foot, no 
recurrence has been observed. Collagenase injection was only effective in treating 
symptomatic LD in this one patient we reported on. (Plast Reconstr Surg Glob Open 
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Two hours of clinical observation followed infiltration (to 
check for systemic reactions related to the procedure). 
The patient was dismissed with recommendation of wear-
ing large running shoes that permit walking and accom-
modation of the dressing.
The patient was assessed postoperatively 3 days after 
injection; he complained of plantar pain (site of injec-
tion) that remitted after acetaminophen assumption. 
Clean bandages were not removed; no bruising or swelling 
of the foot and/or the ankle was detected. After 3 days, 
the patient reported a decrease in plantar pain. The dress-
ing was removed revealing a medium plantar ecchymosis, 
up to the medial aspect of the foot. There was no patho-
logic swelling of the foot. The previously palpable nodule 
of the metatarsophalangeal joint of the first ray was not 
detectable yet.
The patient was satisfied with the treatment. He asked 
for the same treatment for the left foot. Currently, after 
12 months from left side treatment and 14 from right, no 
recurrence has been observed.
DISCUSSION
LD could be treated in several ways, depending on 
the severity of the disease, with uncertain outcomes.1–3,5 
Steroid injections, physiotherapy, extracorporeal shock 
wave therapy, and radiotherapy are currently used.1,2 
Even if nonoperative treatments may not completely 
heal LD, they should be tried before surgical treatment.2 
Surgical treatment is reserved for nonresponsive patients, 
advanced and critically symptomatic disease with walking 
or balancing impairment.2,3 Surgery consists in a complete 
or partial resection of the aponeurosis; in some cases, 
exclusively nodules resection can be performed.3,5 Wound 
closure should be realized with particular care to avoid 
recurrences, pathologic and painful scars, and wound 
dehiscence. In case of surgery, patients should not walk 
until wound closure.
An endoscopic approach could minimize complica-
tions such as wound dehiscence, pathologic scars, or infec-
tions, but nerves injuries, arteries injuries, and disease 
recurrence more easily occur.5
Only open surgical treatment (complete fasciectomy) 
can completely eradicate the disease.3 However, recur-
rence rate is not clearly known.2
The use of CCH for DD is effective with acceptable 
recurrence rates.6 Recurrence rates after CCH injec-
tion are comparable with recurrence rates after surgical 
operation.7
CCH injections should be performed by expert hand 
surgeons, and complications can occur (eg, hematoma, 
skin laceration, neurovascular damage, and tendon 
rupture).4
Unlike LD, DD nodules are rarely symptomatic. 
However, intranodular injection has been already investi-
gated in DD, reducing hardness and size of nodules.8
About the use of CCH in LD, the literature is very 
poor.2,9 Only one study reported a case of CCH injec-
tion in a LD nodule.9 However, the patient previously 
underwent plantar fasciectomy and several steroid injec-
tions, and finally, CCH was injected for 3 times without 
benefits.9
Hammoudeh9 attributed the failure to the anatomo-
pathologic properties of LD that differ from those of DD. 
Differently from our case, CCH injection was performed 
in a previously treated foot (surgery and steroid injec-
tions). In our non-previously treated patient, the absence 
of scar tissue can explain the positive result.
In this study, we report the results from CCH injections 
in a previously untreated patient.
We performed an intranodular injection as first treat-
ment, according to the standard injection technique and 
standard dosage used for DD.4 CCH injection seems to 
have various positive points:
• CCH is a safe drug.4,8
•  Intranodular injection seems to be safe and effective. 
The nodule, which  causes pain, is wide enough to avoid 
the spreading of the drug out of it.
•  Forced extension after injection is not necessary. 
Walking can improve the spreading of the drug into the 
nodule; the plantar aponeurosis will hold its function.
•  Patient can return immediately to normal life, reducing 
the costs of hospitalization and medical care.
Fig. 1. Drug (0.25 mL) was injected into the nodule, dividing the dose into 3 parts, according to the 
standard technique. a, First part is shown. B, second part is shown. C, third one is shown.
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•  Painful scars are avoided.
•  Up to 14- and 12-month follow-up, no recurrence was 
observed. CCH has represented the ultimate solution 
only in one injection to the present day.
Unfortunately, we do not possess enough data to consider 
CCH the gold standard for treatment of LD.
In our experience, differently from Hammoudeh,9 
CCH worked, although we reported the results from a 
single patient (2 injections).
CONCLUSIONS
We wish to emphasize that positive effects cannot 
be neglected. However, the effects of CCH injection in 
LD are poorly documented and little understood. We 
hope that more studies will improve the knowledge 
about this technique. The effects of CCH on very severe 
LD contracture should be further investigated.2,3,9 CCH 
injection is a low-invasive but effective treatment for 
symptomatic LD.
Marta Starnoni, MD
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